<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754464</url>
  </required_header>
  <id_info>
    <org_study_id>Slim-LfX- 2020</org_study_id>
    <nct_id>NCT04754464</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Effect of a Synbiotic on Body Fat Mass</brief_title>
  <official_title>Randomised, Controlled, Double-blind Clinical Study on the Effect of a Synbiotic on Body Fat Mass, Weight Management, Metabolic Syndrome and Other Risk Factors for CVD and Diabetes, on Fecal Microbiota and Adverse Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Slimbiotics GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research Center Kiel GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Slimbiotics GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial the effect of a synbiotic consisting of the three different strains of&#xD;
      Lactobacillus fermentum and acacia gum (gum arabic) on body fat mass, body weight, long-term&#xD;
      glycemia, insulin resistance and other risk factors for CVD and diabetes in overweight type 2&#xD;
      diabetics is investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of probiotics on glucose and lipid metabolism, on body fat, weight, visceral fat&#xD;
      and liver steatosis were shown by several meta-analyses for the total variety, as described&#xD;
      above. Some probiotic species/strains, however, seem to be more efficacious. The lactobacilli&#xD;
      used in this trial were selected for their anti-inflammatory properties and based on&#xD;
      induction of defensins in enterocytes. Therefore, one may expect more pronounced effects of&#xD;
      these strains on traits of the metabolic syndrome, which is driven by low grade inflammation,&#xD;
      than those found in the meta-analyses for the whole variety of probiotics without&#xD;
      discriminating species and strain specificity.&#xD;
&#xD;
      The combination of these Lactobacillus strains with acacia gum is expected to enable even&#xD;
      more pronounce effects, since acacia gum was shown to increase the number of lactobacilli in&#xD;
      the gut and, hence, are supposed to promote their propagation and, hence their effects. The&#xD;
      dosage of 10 g/day acacia gum was demonstrated to be sufficient for enhancing fecal&#xD;
      lactobacilli and bifidobacterial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, controlled, double-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo products are identical with verum in smell, flavour, color, texture, appearance, packaging (sachets) and labelling.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>BFM</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body Fat Mass (BFM) as assessed by bioelectrical impedance analysis (BIA) (alteration V3-V1; verum versus placebo group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glycated Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>HOMA-IR (Homeostasis Model Assessment (HOMA)-IR = glucose [mmol/L] x insulin [µU/ml]/22,5) as parameter for insulin resistance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>WC</measure>
    <time_frame>12 weeks</time_frame>
    <description>Waist Circumference</description>
  </other_outcome>
  <other_outcome>
    <measure>WHtR</measure>
    <time_frame>12 weeks</time_frame>
    <description>waist-to-height ratio</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity, Abdominal</condition>
  <condition>Obesity, Visceral</condition>
  <arm_group>
    <arm_group_label>synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>synbiotic</intervention_name>
    <description>Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water</description>
    <arm_group_label>synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>microcrystalline cellulose</intervention_name>
    <description>Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water</description>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Overweight or obese (BMI ≥ 25)&#xD;
&#xD;
          2. Type 2 diabetes&#xD;
&#xD;
          3. Age ≥ 18&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following is regarded as a criterion for exclusion from enrollment into the&#xD;
        study:&#xD;
&#xD;
          1. Subjects currently enrolled in another clinical study&#xD;
&#xD;
          2. Subjects having finished another clinical study within the last 4 weeks before&#xD;
             inclusion&#xD;
&#xD;
          3. Hypersensitivity, allergy or intolerance against any compound of the test products (e.&#xD;
             g. acacia gum)&#xD;
&#xD;
          4. Condition after implantation of a cardiac pacemaker or other active implants&#xD;
&#xD;
          5. Antidiabetic drugs except metformin&#xD;
&#xD;
          6. Any disease or condition which might compromise significantly the hepatic (ascites),&#xD;
             hematopoietic, renal, endocrine, pulmonary, central nervous, cardiovascular,&#xD;
             immunological, dermatological, gastrointestinal or any other body system with the&#xD;
             exception of the conditions defined by the inclusion criteria&#xD;
&#xD;
          7. History of hepatitis B, C, HIV&#xD;
&#xD;
          8. History of or present liver deficiency as defined by Quick &lt; 70%&#xD;
&#xD;
          9. Regular medical treatment including OTC, which may have impact on the study aims (e.g.&#xD;
             probiotics containing supplements etc.)&#xD;
&#xD;
         10. Major cognitive or psychiatric disorders&#xD;
&#xD;
         11. Subjects who are scheduled to undergo any diagnostic intervention or hospitalization&#xD;
             which may cause protocol deviations&#xD;
&#xD;
         12. Simultaneous study participation by members of the same household&#xD;
&#xD;
         13. Pregnancy and lactation&#xD;
&#xD;
         14. Any diet to lose body weight&#xD;
&#xD;
         15. Eating disorders or vegan diet&#xD;
&#xD;
         16. Anorexic drugs and laxatives&#xD;
&#xD;
         17. Present drug abuse or alcoholism&#xD;
&#xD;
         18. Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Laue, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center Kiel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Slimbiotics GmbH</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24118</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>synbiotic</keyword>
  <keyword>body fat mass</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

